Membranoproliferative Glomerulonephritis

Evidence-Based Nephrology

Volumn , Issue , 2009, Pages 183-195

  Glassock, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Evidence base for treatment decisions; Membrano proliferative glomerulonephritis (MPGN); Membrano proliferative pattern by light microscopy; Nephritis associated with systemic lupus erythematosus (SLE); Nonsteroidal anti inflammatory drugs (NSAIDs); Suggested algorithm for evaluation and treatment of MPGN

Indexed keywords

EID: 78650389328     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303391.ch16     Document Type: Chapter

References (75)

1. Glassock RJ. Membranoproliferative glomerulonephritis In:Ponticelli C, Glassock R, editors. Treatment of Primary Glomerulonephritis, Oxford Medical Publications, Oxford, 1997; 218-233.
2. Holley KE, Donadio JV. Membranoproliferative glomerulonephritis In:Tisher CC, Brenner BM, editors, Renal Pathology (with Clinical and Functional Correlations), 2nd edn. Lippincott and Co., Philadelphia, 1994; 294-329.
3. West CD, McAdams AJ, McConville JM, Davis NC, Holland NH. Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis:clinical and pathologic characteristics. J Pediatr 1965; 67: 1089-1112.
4. Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G et al. Multi-center study of hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007; 49: 69-82.
5. Servais A, Fremeaux-Bacchi V, Salomon R, Lequintrec M, Noel L-H, Knebelman B et al. Mutations in complement regulatory genes, factor H, I and CD46 and C3 nephritic factor predispose to membranoproliferative glomerulonephritiswith isolated mesangial C3 deposits. J Am Soc Nephrol 2005; 16: 51A.
6. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B et al. Primary glomerulonephritis with isolated C3 deposits:a new entity which shares common genetic risk factors with hemolytic uremic syndrome. J Med Genet 2007; 44: 193-199.
7. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P et al. Membranoproliferative glomerulonephritis associated with hepatitis C infection. N Engl J Med 1993; 328: 465-470.
8. Madala ND, Naicker S, Singh B, Naidoo M, Smith AN, Rughubar K. The pathogenesis of membranoproliferative glomerulonephritis in Kwa Zulu-Natal, South Africais unrelated to hepatitis Cvirus infection. Clin Nephrol 2003; 60: 69-73.
9. Asinobi AO, Gbadegesin RA, Adeyemo AA, Akang EE, Arowolo FA, Abi-ola OA et al. The predominance of membranoproliferative glomerulonephritis in childhood nephrotic syndrome in Ibadan, Nigeria. West Afr J Med 1999; 18: 203-206.
10. Johnson RJ, Hurtado A, Merszei J, Rodriguez-Iturbe B, Feng L. Hypothesis:dysregulation of immunologic balance resulting from hygiene and socio-economic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am J Kidney Dis 2003; 42: 575-581.
11. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M et al. Membranoproliferative glomerulonephritis type II (dense deposit disease):an update. J Am Soc Nephrol 2005; 16: 1392-1403.
12. West CD, Witte DP, McAdams AJ. Composition of nephritic-factor generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001; 37: 1120-1130.
13. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20: 605-616.
14. Walker PD. Dense deposit disease:new insights. Curr Opin Nephrol Hy-pertens 2007; 16: 204-212.
15. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type determines renal survival and post-transplant recurrence risk. Kidney Int 2006; 69: 504-511.
16. Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456.
17. Donadio JV, Offord KP. Reassessment of treatment results in membra-noproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989; 14: 445-451.
18. Somers M, Kertesz S, Rosen S, Herrin J, Colvin R, Palaciaos de Carreta N et al. Non-nephrotic children with membranoproliferative glomerulonephritis:are steroids needed? Pediatr Nephrol 1995; 9: 140-144.
19. Cansick JC, Lennon R, Cummins CL, Howie AJ, McGraw ME, Saleem MA et al. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis. Nephrol Dial Transplant 2004; 19: 2769-2777.
20. Wu MJ, Shu KH, Chan LP, Lu YS, Cheng CH, Sheu SS et al. Long-term clinical and morphological evaluation of primary membranoprolifer-ative glomerulonephritis. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57:34-41.
21. Chan MK, Chan KW, Chan PC, Fang GX, Cheng IK. Adult-onset mesan-giocapillaryglomerulonephritis:a disease with a poor prognosis. Q J Med 1989; 72: 599-607.
22. Arslan S, Saatci U, Ozen S, Bakkaloglu A, Besbas N, Tinaztepe K et al. Membranoproliferative glomerulonephritis in childhood:factors affecting prognosis. Int Urol Nephrol 1997; 29: 711-716.
23. Abreo K, Moorthy AV. Type 3 membranoproliferative glomerulonephritis:clinicopathologic correlations and long-term follow-up in nine patients. Arch Pathol Lab Med 1982; 106: 413-417.
24. Iitaka K, Moriya S, Nakamura S, Tomonaga K, Sakai T. Long-term follow-up of type III membranoproliferative glomerulonephritis in children. Pediatr Nephrol 2002; 17: 373-378.
25. Cattran DC, Cardella CJ, Roscoe JM, Charron, RC, Rance PC, Ritchie SM et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 1985; 27: 436M41.
26. Tarshish P, Bernsein J, Tobin JN, Edelmann CM. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone-a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992; 6: 123-130.
27. Donadio JV, Anderson CF, Mitchell JC, Holley CE, Ilstrup DM, Fuster V et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 1984; 310: 1421-1426.
28. Fujita T, Nozu K, Iijima L, Kamioka I, Yoshiya K, Tanaka R. Long-term follow-up of atypical membranoproliferative glomerulonephritis:are steroids indicated? Pediatr Nephrol 2006; 21: 194-200.
29. Mota-Hernandez F, Gordillo-Paniagua G, Munoz-Aripe R. Prednisone vs placebo in membranoproliferative glomerulonephritis:long-term clinico-pathologic correlation. Int J Pediatr Nephrol 1985; 6: 25-28.
30. Zauner I, Bohler J, Braun N, Grupp C, Herring P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic mem-branoproliferative glomerulonephritis. Nephrol Dial Transplant 1994; 9: 619-622.
31. Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U. Prospective trial of warfarin and dipyridamole in patients with membra-noproliferative glomerulonephritis. Am J Med 1983; 75: 920-927.
32. Tiller D, Clarkson A, Mathew T. A prospective randomized trial of the use of cyclophosphamide, dipyridamole and warfarin in membranous and membranoproliferative glomerulonephritis In:Robinson R, Glassock R, Tisher C, Andreoli T, Kokko J. Proceedings of the 8th International Congress of nephrology Karger, Basel, 1981; 345-351.
33. Giri S, Mahajan SK, Sen R, Sharma A. Effects of angiotensin converting enzyme inhibitors on renal function in patients with membranoprolif-erative glomerulonephritis with mild to moderate renal insufficiency. J Assoc Physicians India 2002; 50: 1245-1249.
34. Schena FP. Primary glomerulonephritides with nephrotic syndrome. Limitations of therapy in adult patients. J Nephrol 1999; 12(Suppl 2): S125-S130.
35. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease:nondiabetic nephropathies (REIN). Kidney Int Suppl 2004; 92: S90-S96.
36. McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate day regimen on the natural history of idiopathic mem-branoproliferative glomerulonephritis. Medicine (Baltimore) 1985; 64:401-424.
37. McEnery PT. Membranoproliferative glomerulonephritis:the Cincinnati experience, cumulative renal survival from 1957-1989. J Pediatr 1990; 116: S109-S114.
38. Braun MC, West CD, Strife CF. Difference between membranoproliferative glomerulonephritis type I and III in long-term response to an alternate-dayprednisone regimen. Am J Kidney Dis 1999; 34: 1022-1032.
39. Warady BA, Guggenheim SJ, Sedman A, Lum GM. Prednisone therapy of membranoproliferative glomerulonephritis in children. J Pediatr 1985; 107: 702-707.
40. Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I:limited steroid therapy. Kidney Int 1992; 41: 1606-1612.
41. Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methyl prednisolone and alternate day prednisone therapy. Pediatr Nephrol 1995; 9: 268-271.
42. Yanagihara T, Hayakawa M, Yoshida J, Tsuchiya M, Morita T, Murakami M et al. Long-term follow-up of diffuse membranoproliferative glomerulonephritis type I. Pediatr Nephrol 2005; 20: 585-590.
43. Emre S, Sirin A, Alpay H, Tanman F, Uysai V, Nayir A et al. Pulse methyl-prednisolone therapy in children with membranoproliferative glomerulonephritis. Acta Paediatr Jpn 1995; 37: 626-629.
44. Iitaka K, Ishidate T, Hojo M, Kuwao S, Kasai N, Sakai T. Idiopathic membranoproliferative glomerulonephritis in Japanese children. Pediatr Nephrol 1995; 9: 272-277.
45. Kazama I, Matsubara M, Ejima Y, Michimata M, Suzuki M, Miyama N et al. Steroid resistance in prolonged type I membranoproliferative glomerulonephritis and accelerated disease remission after steroid withdrawal. Clin Exp Nephrol 2005; 9: 62-68.
46. Takeda A, Niimura F, Matsutani H. Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children. Nippon Jinzo Gakkai Shi 1995; 37: 330-335.
47. Bahat E, Akkaya BK, Akman S, Karpuzoglu G, Guven AG. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis. J Nephrol 2007; 20: 234-245.
48. Harmankaya O, Basturk T, Ozturk Y, Karabiber N, Obek A. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 2001; 33: 583-587.
49. Kincaid-Smith P. The treatment of chronic mesangiocapillary (membra-noproliferative) glomerulonephritis with impaired renal function. Med J Aust 1972; 2: 587-592.
50. Chapman SJ, Cameron JS, Chantler C, Turner D. Treatment of mesan-giocapillary glomerulonephritis in children with combined immunosuppression and anti-coagulation. Arch Dis Child 1980; 55: 446-451.
51. Faedda R, Satta A, Tanda F, Pirisi M, Bartole E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994; 67: 59-65.
52. Lagrue G, Laurent J, Beighiti D. Renal survival in membranoproliferative glomerulonephritis (MPGN):role of long-term treatment with nonsteroidal anti-inflammatorydrugs (NSAID). Int Urol Nephrol 1988; 20: 669-677.
53. Vanrenterghem Y, Roels L, Verberckmoes R. Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide. Clin Nephrol 1975; 4: 218-222.
54. Michielsen P, van Damme B, Dotremont G, Verberckmoes R, Oei LS, Vermylen J. Indomethacin treatment of membranoproliferative and lobular glomerulonephritis In:Kincaid-Smith P, T Mathew T, Becker E, editors, Glomerulonephritis. John Wiley and Sons, New York, 1973; 611-620.
55. Kiyomasu T, Shibata M, Kurosu H, Shiraishi K, Hashimoto H, Hayashidera T et al. Cyclosporin Atreatmentformembranoproliferative glomerulonephritis type II. Nephron 2002; 91: 509-511.
56. Matsumoto H, Shibasaki T, Ohno I, Sakai O, Kuriyama S, Tomohari H et al. Effect of cyclosporin monotherapy on proteinuria in patients with membranoproliferative glomerulonephritis. Nippon Jinzo Gakkai Shi 1995; 37: 258-262.
57. Lagrue G, Laurent J, Robeva R. Membranoproliferative glomerulonephritis associated with Buckley's syndrome treated with cyclosporin. Nephron 1986; 44: 382-383.
58. Haddad M, Lau K, Butani L. Remission of membranoproliferative glomerulonephritis type 1 with the use of Tacrolimus. Pediatr Nephrol 2007; 22: 1787-1791.
59. Choi MJ, Eustace JA, Giminez LF, Atta MG, Scheel PJ, Sothinathan R et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
60. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophe-nolate mofetil and steroids. Nephrol Dial Transplant 2004; 19: 3160-3164.
61. Levin ML. Mycophenolate mofetil for primary glomerular diseases (editorial). Kidney Int 2002; 62: 1475.
62. Karim MY, Abbas IC. Mycophenoalte mofetil in non-lupus glomeru-lonephropathy. Lupus 2005; 14(Suppl 1): S39-S41.
63. Bayazit AK, Noyan A, Cengiz N, Anarat A. Mycophenolate mofetil in children with multi-drug resistant nephrotic syndrome. Clin Nephrol 2004; 61: 25-29.
64. Yoshino A, Honda M, Kanegane H, Obata K, Matsukura H, Sakazume S et al. Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia. Pediatr Nephrol 2006; 21: 36-38.
65. Braun MC, Stablein DM, Hamiwka LA, Bell L, Bartosh SM, Strife CF. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts. The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16: 2225-2233.
66. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Cin Apher 2002; 17: 135-137.
67. Lien YH, Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 2000; 35: 539-543.
68. Wu J, Jaar BG, Briggs WA, Choi MJ, Kraus ES, Racusen LC et al. High-dose mycophenolate mofetil in the treatment of post-transplant glomerular disease in the allograft:a case series. Nephron Clin Pract 2004; 98: c61-c66.
69. Licht C, Weyersberg A, Heinen S, Stapenhorst C, Devenge J, Beck B et al. Successful plasma therapy for atypical hemolytic uremia syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45: 515-424.
70. West CD, McAdams AJ, Witte DP. Acute non-proliferative glomerulonephritis:a cause of renal failure unique to children. Pediatr Nephrol 2000; 14: 786-793.
71. Licht C, Schlotzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN-II-genetically determined by defective complement regulation? Pediatr Nephrol 2007; 22: 2-9.
72. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H. Genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151: 1-13.
73. Pickering MC, Cook HT. Translational mini-review series on complement factor H. Renal diseases associated with complement factor H:novel insights from human and animals. Clin Exp Immunol 2008; 151: 210-230.
74. Noris M, Remuzzi G. Translational mini-review series on complement factor H. Therapies of renal diseases associated with complement factor H abnormalities:atypical hemolytic uremic syndrome and membranopro-liferative glomerulonephritis. Clin Exp Immunol 2008; 151: 199-209.
75. Levin A. Management of membranoproliferative glomerulonephritis:evidence-based recommendations. Kidney Int 1999; 46(Suppl 70): S41-S46.